Literature DB >> 20501837

Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development.

Nhu Nam Tran Thang1, Madiha Derouazi, Géraldine Philippin, Séverine Arcidiaco, Wilma Di Berardino-Besson, Frédérick Masson, Sabine Hoepner, Cristina Riccadonna, Karim Burkhardt, Abhijit Guha, Pierre-Yves Dietrich, Paul R Walker.   

Abstract

Immune infiltration of advanced human gliomas has been shown, but it is doubtful whether these immune cells affect tumor progression. It could be hypothesized that this infiltrate reflects recently recruited immune cells that are immediately overwhelmed by a high tumor burden. Alternatively, if there is earlier immune detection and infiltration of the tumor, the question arises as to when antitumor competency is lost. To address these issues, we analyzed a transgenic mouse model of spontaneous astrocytoma (GFAP-V(12)HA-ras mice), which allows the study of immune interactions with developing glioma, even at early asymptomatic stages. T cells, including a significant proportion of Tregs, are already present in the brain before symptoms develop, followed later by macrophages, natural killer cells, and dendritic cells. The effector potential of CD8 T-cells is defective, with the absence of granzyme B expression and low expression of IFN-gamma, tumor necrosis factor, and interleukin 2. Overall, our results show an early defective endogenous immune response to gliomas, and local accumulation of immunosuppressive cells at the tumor site. Thus, the antiglioma response is not simply overwhelmed at advanced stages of tumor growth, but is counterbalanced by an inhibitory microenvironment from the outset. Nevertheless, we determined that effector molecule expression (granzyme B, IFN-gamma) by brain-infiltrating CD8 T-cells could be enhanced, despite this unfavorable milieu, by strong immune stimuli. This potential to modulate the strong imbalance in local antiglioma immunity is encouraging for the development and optimization of future glioma immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20501837     DOI: 10.1158/0008-5472.CAN-09-3074

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses.

Authors:  Ling-Yuan Kong; Adam S Wu; Tiffany Doucette; Jun Wei; Waldemar Priebe; Gregory N Fuller; Wei Qiao; Raymond Sawaya; Ganesh Rao; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2010-10-04       Impact factor: 12.531

Review 2.  Stem cells as therapeutic vehicles for the treatment of high-grade gliomas.

Authors:  Emanuela Binello; Isabelle M Germano
Journal:  Neuro Oncol       Date:  2011-12-13       Impact factor: 12.300

3.  Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy.

Authors:  Courtney A Crane; Brian J Ahn; Seunggu J Han; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2012-03-09       Impact factor: 12.300

4.  Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.

Authors:  Ganesh Rao; Khatri Latha; Martina Ott; Aria Sabbagh; Anantha Marisetty; Xiaoyang Ling; Daniel Zamler; Tiffany A Doucette; Yuhui Yang; Ling-Yuan Kong; Jun Wei; Gregory N Fuller; Fernando Benavides; Adam M Sonabend; James Long; Shulin Li; Michael Curran; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2020-06-18       Impact factor: 12.531

5.  Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype.

Authors:  Kristine Dziurzynski; Jun Wei; Wei Qiao; Mustafa Aziz Hatiboglu; Ling-Yuan Kong; Adam Wu; Yongtao Wang; Daniel Cahill; Nicholas Levine; Sujit Prabhu; Ganesh Rao; Raymond Sawaya; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2011-04-13       Impact factor: 12.531

Review 6.  Immunologic privilege in the central nervous system and the blood-brain barrier.

Authors:  Leslie L Muldoon; Jorge I Alvarez; David J Begley; Ruben J Boado; Gregory J Del Zoppo; Nancy D Doolittle; Britta Engelhardt; John M Hallenbeck; Russell R Lonser; John R Ohlfest; Alexandre Prat; Maurizio Scarpa; Richard J Smeyne; Lester R Drewes; Edward A Neuwelt
Journal:  J Cereb Blood Flow Metab       Date:  2012-10-17       Impact factor: 6.200

Review 7.  Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.

Authors:  David A Reardon; Mark R Gilbert; Wolfgang Wick; Linda Liau
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

8.  Glioma-derived macrophage migration inhibitory factor (MIF) promotes mast cell recruitment in a STAT5-dependent manner.

Authors:  Jelena Põlajeva; Tobias Bergström; Per-Henrik Edqvist; Anders Lundequist; Anna Sjösten; Gunnar Nilsson; Anja Smits; Michael Bergqvist; Fredrik Pontén; Bengt Westermark; Gunnar Pejler; Karin Forsberg Nilsson; Elena Tchougounova
Journal:  Mol Oncol       Date:  2013-09-18       Impact factor: 6.603

9.  Serum GFAP autoantibody as an ELISA-detectable glioma marker.

Authors:  Ping Wei; Wei Zhang; Liu-Song Yang; Hai-Shi Zhang; Xiao-En Xu; Ying-Hua Jiang; Feng-Ping Huang; Qian Shi
Journal:  Tumour Biol       Date:  2013-04-16

10.  Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model.

Authors:  John R Ohlfest; Brian M Andersen; Adam J Litterman; Junzhe Xia; Christopher A Pennell; Lauryn E Swier; Andres M Salazar; Michael R Olin
Journal:  J Immunol       Date:  2012-12-17       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.